Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE:002399)

China flag China · Delayed Price · Currency is CNY
10.77
-0.01 (-0.09%)
Apr 29, 2026, 3:04 PM CST
-0.65%
Market Cap 14.36B
Revenue (ttm) 5.48B
Net Income (ttm) 349.49M
Shares Out 1.47B
EPS (ttm) 0.24
PE Ratio 45.21
Forward PE 19.23
Dividend 0.15 (1.35%)
Ex-Dividend Date n/a
Volume 4,296,862
Average Volume 4,129,924
Open 10.92
Previous Close 10.78
Day's Range 10.72 - 10.94
52-Week Range 10.30 - 14.34
Beta 0.44
RSI 37.83
Earnings Date Apr 29, 2026

About SHE:002399

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium APIs. It also provides molecule biologics CDMO services, which include... [Read more]

Sector Healthcare
Founded 1998
Employees 2,150
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002399
Full Company Profile

Financial Performance

In 2025, SHE:002399's revenue was 5.48 billion, an increase of 3.75% compared to the previous year's 5.28 billion. Earnings were 349.49 million, a decrease of -45.96%.

Financial Statements

News

There is no news available yet.